A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence

Of the only 20% of patients with resectable pancreatic ductal adenocarcinoma (rPDA), cancer recurs in 80% of cases. Epigenetic dysregulation is an early hallmark of cancer cells acquiring metastatic potential,...

Source: Clinical Epigenetics - December 3, 2022 Category: Research Authors: Thatcher R. Heumann, Marina Baretti, Elizabeth A. Sugar, Jennifer N. Durham, Sheila Linden, Tamara Y. Lopez-Vidal, James Leatherman, Leslie Cope, Anup Sharma, Colin D. Weekes, Peter J. O ’Dwyer, Kim A. Reiss, Dulabh K. Monga, Nita Ahuja and Nilofer S. A Tags: Research Source Type: research